ABIRATERONE AND PREDNISOLONE

Brand name:

• Andriga-10

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

ACTOR PHARMACEUTICALS PTY LTD

Condition/indication:
(therapeutic use)

• Castration resistant carcinoma of the prostate

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New PBS listing (–)

Comment:

--

Other PBAC consideration:

--

Submission received for:

July 2025 PBAC meeting

Opportunity for consumer comment:

Open 02/04/2025 and close 28/05/2025 (see PBS Website)

PBAC meeting:

Held on 09/07/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

29/09/2025

Lodgement of required documentation:

07/10/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 22/10/2025

Status:

Finalised

Government processes:

Commenced on 07/11/2025

Medicine listed on the PBS:

01/02/2026 (see PBS schedule)